---
document_datetime: 2025-11-13 09:45:43
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sitagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: sitagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.2654019
conversion_datetime: 2025-12-23 03:47:39.677349
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0003              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 19/04/2024                                  |                                             | SmPC and PL                      |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

Sitagliptin/Metformin Hydrochloride Accord Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0002/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an   | 17/11/2022                                       | n/a           | longer          |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|---------------|-----------------|
| IAIN/0001   | ASMF B.II.b.2.c.1 - Change to importer, batch arrangements and quality control testing Replacement or addition of a manufacturer responsible for importation and/or batch Not including batch control/testing Medicinal                                                                                                                                                                                                                                                                                                    | release of the FP - release - 31/08/2022 product | 15/09/2023 no | Annex II and PL |